BRSYF Stock Chart & Stats
$15.13
$0.00(0.00%)
At close: 4:00 PM EDT
$15.13
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$5.49 - $18.88
Previous CloseN/A
Volume20.00
Average Volume (3M)0.00
Market Cap
$564.39M
Enterprise Value$1.68K
Total Cash (Recent Filing)$61.94M
Total Debt (Recent Filing)$7.13M
Price to Earnings (P/E)63.2
Beta0.52
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.24
Shares Outstanding40,207,980
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)5.11
Price to Sales (P/S)6.62
P/FCF Ratio23.00
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Margin ExpansionSustained growth alongside the 12th consecutive profitable quarter indicates improving operating leverage. Strong gross margins and expanding EBITDA support a more durable earnings model as Deep TMS adoption scales.
Installed Base And BacklogA larger installed base supports recurring utilization, consumables and service revenue. Rising RPO adds forward visibility and indicates demand for placements, although conversion depends on execution and contract timing.
Conservative Balance SheetLow leverage and substantial cash provide financial flexibility to fund clinical development, commercial expansion and strategic investments. This reduces refinancing risk and gives BrainsWay capacity to absorb execution variability.
Bears Say
Cash Flow VolatilityWeakening cash conversion despite improved profitability suggests working-capital swings or higher cash costs. If persistent, this could limit internally funded growth and make reported earnings less representative of cash generation.
Uneven Reimbursement AdoptionReimbursement is central to clinic economics and patient access for TMS. Uneven payer decisions can slow system placements and utilization across markets, limiting the pace at which clinical evidence converts into recurring revenue.
Operating Cost PressureHigher clinical-development and administrative spending can constrain operating leverage if revenue growth moderates. Continued investment may support future products, but it also raises execution demands and creates risk to margin sustainability.
Brainsway News
BRSYF FAQ
What was Brainsway Ltd’s price range in the past 12 months?
Brainsway Ltd lowest stock price was $5.49 and its highest was $18.88 in the past 12 months.
What is Brainsway Ltd’s market cap?
Brainsway Ltd’s market cap is $564.39M.
When is Brainsway Ltd’s upcoming earnings report date?
Brainsway Ltd’s upcoming earnings report date is Nov 18, 2026 which is in 66 days.
How were Brainsway Ltd’s earnings last quarter?
Brainsway Ltd released its earnings results on Aug 12, 2026. The company reported $0.068 earnings per share for the quarter.
Is Brainsway Ltd overvalued?
According to Wall Street analysts Brainsway Ltd’s price is currently Overvalued.
Does Brainsway Ltd pay dividends?
Brainsway Ltd does not currently pay dividends.
What is Brainsway Ltd’s EPS estimate?
Brainsway Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Brainsway Ltd have?
Brainsway Ltd has 40,207,980 shares outstanding.
What happened to Brainsway Ltd’s price movement after its last earnings report?
Brainsway Ltd reported an EPS of $0.068 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Brainsway Ltd?
Currently, no hedge funds are holding shares in BRSYF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Brainsway Ltd
Established in Jerusalem, Israel, in 2003, BrainsWay Ltd. specializes globally in creating and distributing advanced, non-invasive neurostimulation therapies designed to address a wide array of mental health and neurological conditions. The company's primary innovation is its Deep Transcranial Magnetic Stimulation (dTMS) platform, which offers treatment for disorders including major and anxious depression, obsessive-compulsive disorder, nicotine addiction, bipolar disorder, post-traumatic stress disorder, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's solutions are primarily adopted by psychiatric practitioners, hospitals, and medical centers across the United States, Europe, Israel, and other international markets.
BRSYF Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call portrayed strong operational and financial momentum: robust revenue growth (+35%), substantial margin and profitability expansion (operating income >300%, adjusted EBITDA +141%, margin expansion to 20%), growing installed base (+42% systems placed) and a larger, more visible backlog (+30% RPO). Clinical and reimbursement progress (SWIFT durability data, 57M covered lives, >83% PTSD response in a 462‑patient study) and strategic minority investments support a multi‑year growth thesis. Notable cautions include rising R&D and G&A spend, uneven reimbursement adoption across markets, conditionality/uncertainty around Neurolief and wide forecast ranges for margins/EBITDA, and revenue timing risk from backlog. On balance, positive operational trends, cash strength and improved visibility outweigh the highlighted risks.View all BRSYF earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
0.23% Mutual Funds
0.23% Other Institutional Investors
98.90% Public Companies and
Individual Investors